Argenx agrees to buy Unnatural Products for $550 million upfront, plus milestones, to add oral peptide drugs to its immunology pipeline

From the source

Argenx agrees to buy Unnatural Products for $550 million upfront, plus milestones, to add oral peptide drugs to its immunology pipeline

Argenx agreed on Monday to buy Unnatural Products (UNP), a Santa Cruz, California company that designs macrocyclic peptides, for $550 million in cash upfront and up to $595 million in payments tied to development and regulatory milestones [1] . Total potential consideration is up to about $1.15 billion. Argenx already holds a minority stake in UNP and will buy the remaining shares; both boards hav